Global Radiation Dose Management Market is Expecting Worldwide Growth

The rising concern associated with radiation exposure, increasing awareness and industry initiatives regarding the issue, and surging prevalence of chronic diseases are some of the factors responsible for the growth of the radiation dose management market. In 2016, the market generated a revenue of $129.8 million, and it is expected to attain a size of more than $1700.0 million by 2023, advancing at a CAGR of 46.0% during the forecast period (2017–2023).

RDM refers to a solution that can be integrated with medical systems, such as electronic health record (EHR), picture archiving and communication system (PACS), and radiology information system (RIS), to monitor, archive, and track the radiation exposure and aid in improving patient safety. Based on product, the radiation dose management market is bifurcated into solutions and services. Of these, during the historical period (2013–2016), solutions dominated the market, and these are projected to continue dominating it during the forecast period.

To Learn More About this Report: http://bit.ly/2qc1H4g

One of the main purposes of radiological protection is to prevent the patient from the adverse effects of radiation. Exposure to high radiation doses over a short period can sometimes cause life-threating diseases, such as cancer and radiation sickness, symptomized by fainting, nausea, vomiting, hair loss, diarrhea, bleeding, confusion, and mouth and skin sores. Radiation exposure not only affects patients, but it can also affect the public, as well as those inside medical and emergency settings. Therefore, the need to check radiation exposure is boosting the growth of the radiation dose management market.

For instance, as per the United States Food and Drug Administration (USFDA), for nuclear medicine, the average adult effective dose is between 0.2 and 416 mSv and estimated dose equivalent (no. of chest X-rays) is 10–2050. Further, the incidence of chronic diseases, such as chronic obstructive pulmonary disease, cancer, hepatitis, acquired immunodeficiency syndrome, and cardiovascular diseases, is growing. These diseases are diagnosed by different imaging techniques, such as CT scan, which need various radioactive compounds to detect the disease.

Hence, the growing awareness on the adverse effects of radiation exposure, governments’ surging initiatives, and increasing incidence of chronic diseases are predicted to augment the market growth.